Outcome of children less than three years old at diagnosis with non‐metastatic medulloblastoma treated with chemotherapy on the “Head Start” I and II protocols
Pediatric Blood & Cancer2008Vol. 50(6), pp. 1169–1175
Citations Over TimeTop 10% of 2008 papers
Girish Dhall, Howard Grodman, Lingyun Ji, Stephen A. Sands, Sharon L. Gardner, Ira J. Dunkel, Geoffrey McCowage, Blanca Diez, Jeffrey C. Allen, Anjali Gopalan, Albert Cornelius, Amanda Termuhlen, Minnie Abromowitch, Richard Sposto, Jonathan L. Finlay
Abstract
This strategy of brief intensive chemotherapy for young children with non-metastatic medulloblastoma eliminated the need for craniospinal irradiation 52% of the patients, and may preserve QoL and intellectual functioning. The excellent survival rates are somewhat dampened by high toxic mortality.
Related Papers
- → Chemotheraphy of Medulloblastoma(1968)2 cited
- → Simultaneous Resistance to Vincristine and Adriamycin Appears at Higher Frequencies Than to Vincristine and Etoposide in Chinese Hamster Ovary Cells(1993)1 cited
- [Phase II study with etoposide/vincristine in small cell bronchial cancer (extensive disease)].(1990)
- → Randomised trial of etoposide cyclophosphamide methotrexate and vincristine versus etoposide and vincristine in the palliative treatment of patients with small cell lung cancer (SCLC) and poor prognosis(1994)1 cited